Seqtara is a peptide immunogenicity risk assessment platform built for biopharmaceutical researchers and regulatory scientists.
Seqtara predicts immunogenicity risk (MHC class II binding potential + self TCR evaluation) using a curated panel of 23 human alleles, making it suitable for early-stage immunogenicity screening of biologic drugs, impurities, and related peptide variants.
FASTA Input
Seqtara accepts single or multi-peptide FASTA files. Sequences can be loaded from a file (drag-and-drop or browse) or typed/pasted directly into the built-in editor. On the desktop, a native file picker dialog is available. Whatever is loaded is displayed in the editable text area — you can review or modify sequences before running.
Evaluation Modes
Individual: Each peptide is scored independently across the selected alleles.
Compare against API: One peptide is designated the Active Pharmaceutical Ingredient (API); all others are scored relative to it, highlighting sequences with elevated risk compared to the reference.
Both: Runs individual and comparison in a single pass (multi-peptide only).
Seqtara evaluates peptide sequences against a curated panel of 23 human MHC class II alleles, selected to represent the breadth of immunogenically relevant HLA diversity in the global population.
When running an evaluation, you can restrict scoring to a subset of loci using the Allele groups selector in the evaluation options dialog. This is useful when:
The progress indicator and allele counts in the report always reflect the filtered set.
Evaluate sequence-based information for:
